Duality Advisers LP reduced its position in AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) by 31.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 111,041 shares of the company’s stock after selling 51,159 shares during the period. Duality Advisers LP’s holdings in AbCellera Biologics were worth $634,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the company. Handelsbanken Fonder AB boosted its holdings in shares of AbCellera Biologics by 13.5% in the 4th quarter. Handelsbanken Fonder AB now owns 45,400 shares of the company’s stock valued at $259,000 after buying an additional 5,400 shares in the last quarter. Signaturefd LLC boosted its stake in AbCellera Biologics by 306.3% in the 4th quarter. Signaturefd LLC now owns 10,596 shares of the company’s stock worth $61,000 after purchasing an additional 7,988 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in AbCellera Biologics by 352.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,566 shares of the company’s stock worth $192,000 after purchasing an additional 26,143 shares in the last quarter. JGP Global Gestao de Recursos Ltda. acquired a new stake in AbCellera Biologics in the 4th quarter worth approximately $99,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in AbCellera Biologics in the 4th quarter worth approximately $62,000. 61.42% of the stock is currently owned by institutional investors.
AbCellera Biologics Trading Down 1.8 %
Shares of NASDAQ ABCL opened at $3.90 on Thursday. AbCellera Biologics Inc. has a 12 month low of $3.79 and a 12 month high of $8.05. The company has a 50 day simple moving average of $4.63 and a two-hundred day simple moving average of $4.81. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -7.50 and a beta of 0.36.
Analyst Upgrades and Downgrades
A number of analysts recently commented on ABCL shares. Stifel Nicolaus lowered their target price on shares of AbCellera Biologics from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 21st. Benchmark upgraded shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a research note on Thursday, February 22nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AbCellera Biologics presently has a consensus rating of “Buy” and a consensus target price of $15.86.
Read Our Latest Report on AbCellera Biologics
AbCellera Biologics Profile
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
See Also
- Five stocks we like better than AbCellera Biologics
- When to Sell a Stock for Profit or Loss
- Simpson Manufacturing: Buy This Future Dividend King While Down
- What Are the FAANG Stocks and Are They Good Investments?
- Is Boeing Stock About to Soar Higher?
- What is a Secondary Public Offering? What Investors Need to Know
- High-Yield Texas Instruments Could Hit New Highs Soon
Want to see what other hedge funds are holding ABCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report).
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.